Clinical Trial Update: Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial TASKI-1 evaluating a Syk kinase inhibitor for rheumatoid arthritis has completed. The study was sponsored by Rigel Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Fostamatinib (fostamatinib)

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED